<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04979884</url>
  </required_header>
  <id_info>
    <org_study_id>cyclosporine in COVID-19</org_study_id>
    <nct_id>NCT04979884</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness of Cyclosporin in the Management of COVID19 ARDS Patients in Alexandria University Hospital</brief_title>
  <official_title>Safety and Therapeutic Efficacy of Cyclosporine Plus Standard of Care Treatment on ARDS in COVID -19 Patients at Alexandria University Hospitals in 2021: a Comparative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alexandria University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Science and Technology Development Fund (STDF), ,Egypt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Alexandria University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study to evaluate the effect of cyclosporine ( IL2 inhibitor and antiviral) verse&#xD;
      standard care treatment on decrease ADRS, hyper inflammation, hypercytokinemia, and the&#xD;
      mortality rate&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To test the efficacy of IL-2 inhibitors (Cyclosporine) compared to the Standard of care&#xD;
      according to hospital protocol on COVID-19 patients concerning the clinical outcome&#xD;
      (cytokines level, clinical improvement, and PCR of sARS-CoV-2 through the study period).&#xD;
&#xD;
      AIM:&#xD;
&#xD;
      The slow progression of the disease, improving survival among COVID-19 patients, and Standard&#xD;
      assessment of patient improvement.&#xD;
&#xD;
        -  Standard assessment of patient improvement:&#xD;
&#xD;
        -  PCR-SARS-CoV-2 negative&#xD;
&#xD;
        -  No fever&#xD;
&#xD;
        -  No cytopenia (Hb ≥90 g/L, ANC ≥0.5x109/L, platelets ≥100x109/L) •&#xD;
&#xD;
        -  No hyperferritinemia ≥500 μg/L&#xD;
&#xD;
        -  (Decrease of IL2)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2021</start_date>
  <completion_date type="Anticipated">April 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of subjects with a 6-point ordinal scale showing each severity level</measure>
    <time_frame>7-14 days after randomization</time_frame>
    <description>i. Death ii. Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation iii. Hospitalized, on non-invasive ventilation or high flow oxygen devices iv. Hospitalized, requiring supplemental oxygen v. Hospitalized, not requiring supplemental oxygen vi. Not hospitalized</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of hospital admission</measure>
    <time_frame>through study completion, an average of 4 weeks</time_frame>
    <description>efficacy of CsA in reducing days in hospital</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of decline OF Soluble interleukin-2 (IL-2) receptor alpha. (sCD25)</measure>
    <time_frame>Days 1, 8, 15 or at hospital discharge(through study completion, an average of 6 weeks)</time_frame>
    <description>change from baseline in IL-2 levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of decline OF interleukin-1</measure>
    <time_frame>Days 1, 8, 15 or at hospital discharge(through study completion, an average of 6 weeks)</time_frame>
    <description>change from baseline in IL-1 levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of decline OF interleukin-10(IL-10)</measure>
    <time_frame>Days 1, 8, 15 or at hospital discharge(through study completion, an average of 4 weeks)</time_frame>
    <description>change from baseline in IL-10 levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of decline OF Interleukin-6,( IL-6)</measure>
    <time_frame>Days 1, 8, 15 or at hospital discharge(through study completion, an average of 4 weeks)</time_frame>
    <description>change from baseline in IL-6levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of decline OF Tumour necrosis factor α (TNFα)</measure>
    <time_frame>Days 1, 8, 15 or at hospital discharge(through study completion, an average of 4 weeks)</time_frame>
    <description>change from baseline in TNFα levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to 50% a decrease of ferritin levels compared to peak value during trial</measure>
    <time_frame>up to 28 days</time_frame>
    <description>change from baseline in ferritin levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lung imaging improvement time</measure>
    <time_frame>up to 28 days</time_frame>
    <description>COVID19 Lung imaging determination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time for non-invasive or invasive initial use</measure>
    <time_frame>during hospital admission (up to 28 days)]</time_frame>
    <description>efficacy of CSA in reducing days of ventilators</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to improvement in oxygenation</measure>
    <time_frame>up to 28 days) from hospitalization</time_frame>
    <description>defined as independence from supplemental oxygen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days safe from ventilators</measure>
    <time_frame>during hospital admission (up to 28 days)</time_frame>
    <description>efficacy of CSA in reducing days of ventilators</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days on mechanical ventilation</measure>
    <time_frame>during hospital admission (up to 28 days)</time_frame>
    <description>to evaluate the efficacy of CSA in reducing days of ventilators</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of days in the intensive care unit after randomization</measure>
    <time_frame>during hospital admission (up to 28 days)]</time_frame>
    <description>to evaluate the efficacy of CSA in reducing days in the intensive care unit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of (Adverse Events) and Incidence of nosocomial bacterial or invasive fungal infection</measure>
    <time_frame>during hospital admission (up to 28 days)]</time_frame>
    <description>to evaluate the safety of CSA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change of SOFA score in ICU patients</measure>
    <time_frame>between 1, 15 days) hospital discharge</time_frame>
    <description>The Sequential Organ Failure Assessment (SOFA) score: 0 (best) - 24 (worse) The SOFA score will be used to assess the probability of organ failure and mortality in ICU patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean improvement in Clinical Deterioration Changed Early Warning Score (MEWS) between 1, 15 days)</measure>
    <time_frame>between 1, 15 days) hospital discharge</time_frame>
    <description>efficacy of CsA in Clinical improvement</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of Mortality</measure>
    <time_frame>throughout 30 and 90 days</time_frame>
    <description>efficacy of CsA in reducing mortality</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>all-cause mortality will be measured.</measure>
    <time_frame>At 28, 30, and 90 days,</time_frame>
    <description>efficacy of CsA in reducing mortality</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>COVID-19 Acute Respiratory Distress Syndrome</condition>
  <condition>Cytokine Release Syndrome</condition>
  <condition>Pulmonary Fibrosis</condition>
  <arm_group>
    <arm_group_label>cyclosporine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients will receive cyclosporine + (standard care treatment (± anticoagulant± antibiotic± antipyretic± steroid) according to Alexandria university hospitals protocol )</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients will receive standard treatment (antiviral ± anticoagulant± antibiotic± antipyretic± steroid± interleukin ) according to Alexandria university hospitals protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <description>Dose of Cyclosporine oral capsule of 6 mg/kg/day divided into two doses with normal kidney function for 8-14 days</description>
    <arm_group_label>Standard of care treatment</arm_group_label>
    <arm_group_label>cyclosporine</arm_group_label>
    <other_name>interleukin-2</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Current infection with COVID-19&#xD;
&#xD;
          2. written informed consent&#xD;
&#xD;
          3. Confirmed diagnosis of COVID-19 by PCR and/or Positive Serology or any existing and&#xD;
             validated diagnostic COVID-19 parameters during this time.&#xD;
&#xD;
          4. 18yrs ≥ Age &lt;66 yrs&#xD;
&#xD;
          5. Chest X-ray showing suggestive of COVID-19 disease.&#xD;
&#xD;
          6. Both gender&#xD;
&#xD;
          7. The presence of Pulmonary fibrosis or hyper inflammation signs or A syndrome of&#xD;
             cytokine release defined as ANY of the following::&#xD;
&#xD;
               1. Leukopenia or lymphopenia,&#xD;
&#xD;
               2. Ferritin &gt; 500ng/mL or D-dimers ≥ 500 ng/mL&#xD;
&#xD;
               3. Hs&gt;90&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Lactation and Pregnancy women&#xD;
&#xD;
          2. unlikely to survive beyond 48h&#xD;
&#xD;
          3. Need for mechanical ventilation.&#xD;
&#xD;
          4. cases of multiorgan failure or abnormal renal function and shock.&#xD;
&#xD;
          5. malignancies, autoimmune disease, Perforation of the bowels or diverticulitis.&#xD;
&#xD;
          6. active bacterial or fungal infection.&#xD;
&#xD;
          7. We define impairment of cardiac function as poorly controlled heart diseases, cardiac&#xD;
             insufficiency, unstable angina pectoris, myocardial infarction within 1 year before&#xD;
             enrollment, supraventricular or ventricular arrhythmia needs treatment or&#xD;
             intervention, Uncontrolled hypertension (&gt;180/110 mmHg.&#xD;
&#xD;
          8. Levels of serum transaminase &gt;5 upper references rang&#xD;
&#xD;
          9. Symptoms of active tuberculosis or human immunodeficiency virus (HIV) positivity&#xD;
&#xD;
         10. the patient receiving Vaccines: Live, attenuated vaccines&#xD;
&#xD;
         11. Subjects received monoclonal antibodies within one week before admission.&#xD;
&#xD;
         12. Patients receiving high-dose systemic steroids (&gt; 20 mg methylprednisolone or&#xD;
             equivalent), immunosuppressant or immunomodulatory drugs&#xD;
&#xD;
         13. Contraindications for use in people with psoriasis include concomitant treatment with&#xD;
             methotrexate, other immunosuppressant agents, coal tar, or radiation therapy.&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maged El-Setouhy</last_name>
    <role>Study Director</role>
    <affiliation>Alexandria University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amira zidane</last_name>
    <phone>00201024585329</phone>
    <email>amira.zidan2yahoo@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ahmed Gad</last_name>
    <phone>00201144666619</phone>
    <email>ahmedyoussf0416@gmail.com</email>
  </overall_contact_backup>
  <reference>
    <citation>Fellman CL, Archer TM, Wills RW, Mackin AJ. Effects of cyclosporine and dexamethasone on canine T cell expression of interleukin-2 and interferon-gamma. Vet Immunol Immunopathol. 2019 Oct;216:109892. doi: 10.1016/j.vetimm.2019.109892. Epub 2019 Jul 11.</citation>
    <PMID>31446206</PMID>
  </reference>
  <reference>
    <citation>Damaso CR, Keller SJ. Cyclosporin A inhibits vaccinia virus replication in vitro. Arch Virol. 1994;134(3-4):303-19.</citation>
    <PMID>8129618</PMID>
  </reference>
  <reference>
    <citation>Ciesek S, Steinmann E, Wedemeyer H, Manns MP, Neyts J, Tautz N, Madan V, Bartenschlager R, von Hahn T, Pietschmann T. Cyclosporine A inhibits hepatitis C virus nonstructural protein 2 through cyclophilin A. Hepatology. 2009 Nov;50(5):1638-45. doi: 10.1002/hep.23281.</citation>
    <PMID>19821520</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 14, 2021</study_first_submitted>
  <study_first_submitted_qc>July 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 28, 2021</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Cyclosporine</keyword>
  <keyword>secondary haemophagocytic lymphohistiocytosis (sHLH)</keyword>
  <keyword>acute respiratory distress syndrome (ARDS)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
    <mesh_term>Respiratory Distress Syndrome</mesh_term>
    <mesh_term>Respiratory Distress Syndrome, Newborn</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Pulmonary Fibrosis</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Cytokine Release Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Interleukin-2</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

